Voo ETF News

https://www.investing.com/news/stock-market-news/sp-500-plunges-as-putin-said-to-give-go-ahead-for-ukraine-invasion-2762550

S&P 500 Plunges as Putin Said to Give Go Ahead for Ukraine Invasion

S&P 500 Plunges as Russia Said to Prepare Ukraine Invasion

Investors should expect to see fewer Food and Drug Administration approvals of copycat PD-L1 therapies after an advisory committee recommended against approving an experimental cancer drug, according to SVB Leerink analysts. The drug in question, sintilimab, is being developed by Innovent Biologics Inc. , a Chinese drug maker, and Eli Lilly & Co. . The FDA''s Oncologic Drugs Advisory Committee on Thursday voted against approving the drug as a frontline non-small cell lung cancer treatment; the main trial for the drug was conducted in China, and the committee said it wants additional studies assessing the therapy in the U.S. population. More broadly, the vote may be an indicator for how other copycat PD-L1 therapies will be viewed by U.S. regulators, the analysts said. "Were [the trial] a one-off case, we sense that the FDA may be more willing to grant approval, but given its status as a leading example, we believe the FDA will draw a line in the sand to discourage this single-country trial approach," SVB Leerink analyst Daina Graybosch told investors on Friday.

Dow may be the only major indices to gain this week as investors balance strong corporate earnings against potential rage hikes

February 11, 2022 (Investorideas.com Newswire) S&P 500 upswing was rejected - the intraday comeback didn''t succeed. Risk-off posture won the day, and the dust is settling.

The real estate sector of the S&P 500 has made an about-face move in 2022 as it is the worst-performing market segment after being a top-performing area in 2021.

The investment firms private-equity portfolio appreciated by 5.2% in the quarter, falling short of the 11% gain for the S&P 500.

The S&P 500 has seen a more decisive rejection of key resistance at 4591/95. Analysts at Credit Suisse expect to see an important cap here in line wit

The tone in US equities has improved in the past two hours, in part due to a CNBC story highlighting that some Fed officials aren''t eager to chance their stance on gradual rate hikes. S&P 500 futures are up 5 points after yesterday''s 83-point decline. Nasdaq and Dow futures are also up aro

Europe''s STOXX 600 was down 0.9%, Nasdaq and S&P 500 futures were down 0.7% and 0.5% respectively

Our call of the day says this market is down, but not out yet. Mark Newton, head of technical strategy at Fundstrat, is watching out for some key equity…

After the first bearish reaction on the USD after US CPI yesterday, the currency turned down later during the US session.

European indices are keeping lower so far on the session, with the Eurostoxx down 0.9%, the DAX down 0.4%, CAC 40 down 1.3%, and UK FTSE down 0.8%. Meanwhile, S&P 500 futures are down 0.5%, Nasdaq futures down 0.7%, and Dow futures down 0.4%.The losses are somewhat trimmed from earlier in the day bu

The years top-performing S&P 500 sectors are those that ended 2021 with the lowest price-to-earnings ratios.